System and methods for performing saliva-based diagnostic screenings
US-2024420847-A1 · Dec 19, 2024 · US
Diagnostic and therapeutic methods and products related to anxiety disorders
US10228378B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10228378-B2 |
| Application number | US-201715614448-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 5, 2017 |
| Priority date | Feb 1, 2011 |
| Publication date | Mar 12, 2019 |
| Grant date | Mar 12, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides methods for diagnosing and treating anxiety disorders in female subjects. Diagnosis and treatment of such anxiety disorders are based, in part, on an analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in tissue collected from female subjects.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for diagnosing an anxiety disorder in a subject, comprising: a. collecting a DNA sample from the subject; b. analyzing the DNA sample for the presence of a SNP in a PAC1 receptor gene and/or for epigenetic methylation at a first site within a ADCYAP1R1 CpG island; c. diagnosing the anxiety disorder in the subject having the SNP in the PAC1 receptor gene and/or having elevated levels of epigenetic methylation; and d. administering a therapeutically effective amount of a PACAP inhibitor or PACAP receptor antagonist. 2. The method of claim 1 , wherein the anxiety disorder is PTSD. 3. The method of claim 1 , wherein the gene encoding the PAC1 receptor is ADCYAP1R1. 4. The method of claim 3 , wherein the SNP is located at position rs2267735 of the ADCYAP1R1 gene. 5. The method of claim 4 , wherein the SNP is a G→C allelic mutation. 6. The method of claim 1 , wherein the subject has been exposed to a trauma.
Assignees
Inventors
Classifications
Expression markers · CPC title
for diseases caused by alterations of genetic material · CPC title
Methylation markers · CPC title
Anxiety or phobic disorders · CPC title
- G01N33/6893Primary
related to diseases not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10228378B2 cover?
- The present disclosure provides methods for diagnosing and treating anxiety disorders in female subjects. Diagnosis and treatment of such anxiety disorders are based, in part, on an analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in tissue collected from female subjects.
- Who is the assignee on this patent?
- The Univ Of Vermont And State Agricultural College, Univ Emory
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6893. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).